Bio X Cell

In Vivo Monoclonal Antibodies (Mabs) | Isotype Controls | InVivoSIM™ Biosimilar Antibodies | RecombiMAb™ | Functional Bispecific Solutions | PD-1 | TIGIT, TIM-3, LAG-3 | Reagents

About Bio X Cell

For more than 25 years, scientists have trusted Bio X Cell as their go-to source for in vivo functional grade antibodies. Bio X Cell take this responsibility to heart and have always focused their efforts on one goal: producing the highest-quality antibodies with the best value possible. By doing this, they help scientists research with confidence and discover faster.

Bio X Cell unwavering commitment to scientists has inspired them to create and optimize a proprietary in vivo antibody manufacturing method with significant advantages that directly benefit their customers.

Their industry-leading InVivoMAb™ and InVivoPlus™ antibodies are all manufactured in their own facility in the US and never outsourced from another manufacturer, giving them full control over the quality and availability of their products.

“I am totally satisfied with the service Bio X Cell has given us. When anyone asks me for CTLA-4 antibodies, I always refer them to you. I look forward to another 20 years.”

– James P. Allison (2018 Nobel Prize Corecipient in Physiology or Medicine)

Bio-Connect supplies all their products in the Benelux. If you have any questions, please contact the helpdesk.

Major product lines from Bio X Cell

Autoimmunity Cytokine Targets

  • FcRn – Myasthenia gravis, ITP, LGI1 FcRn encephalitis
  • IL-36R – Generalized pustular psoriasis
  • IFNAR1 – Systemic lupus erythematosus (SLE)
  • IL-5/IL-5R – Eosinophilic asthma, EGPA
  • IL-17A/IL-23 (p19) – Psoriasis, Psoriatic arthritis, Crohn
  • IL-6R – Rheumatoid arthritis, Giant cell arteritis
  • BAFF (BLyS) – SLE

Antibody Targets for Neurological Disorders

  • Amyloid-β (protofibrils) – Early Alzheimer’s disease
  • Tau protein – Alzheimer’s disease, Tau protein dementia
  • Aggregated α-synuclein – Parkinson’s disease
  • CGRP – Migraine
  • TREM2 receptor – Alzheimer’s disease

Contract antibody production service

At Bio X Cell, they know that growing hybridoma cells and purifying antibodies in the quantities needed for in vivo pre-clinical research can be technically challenging and time-consuming. For over 20 years, their industry-leading antibodies and antibody production services have allowed their customers more time to focus on accelerating research discoveries. Their platform focuses on antibody production from pre-existing hybridoma cell lines, and is easily scalable to deliver the large quantities required for in vivo research. Contact your account manager for more information.

Educational Resources

Top sellers

Publications

  • Front Immunol. 2018;9:2100.

    Grasselly C, et al. The antitumor activity of combinations of cytotoxic chemotherapy and immune checkpoint inhibitors is model-dependent.

  • Immunity. 2018;49(2):247-263.e7.

    Stathopoulou C, et al. Pd-1 inhibitory receptor downregulates asparaginyl endopeptidase and maintains foxp3 transcription factor stability in induced regulatory t cells.

  • PLoS One. 2018;13(6):e0197702.

    Balogh KN, et al. Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses.

  • Cancer Cell. 2018;34(5):757-774.e7.

    Wang W, et al. Rip1 kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer.

  • Cancer Immunol Res. 2018;6(2):189-200.

    Ariyan CE, et al. Robust antitumor responses result from local chemotherapy and ctla-4 blockade.

  • Clin Cancer Res. 2015;21(5):1127-1138.

    Dai M, et al. Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.

  • Photochem Photobiol. 2019;95(1):430-438.

    Davis RW, et al. Luminol chemiluminescence reports photodynamic therapy-generated neutrophil activity in vivo and serves as a biomarker of therapeutic efficacy.

  • Immunity. 2018;48(4):760-772.e4.

    Burrack KS, et al. Interleukin-15 complex treatment protects mice from cerebral malaria by inducing interleukin-10-producing natural killer cells.

  • J Immunol. 2015;195(3):1064-1070.

    Wynn JL, et al. Neonatal cd71+ erythroid cells do not modify murine sepsis mortality.

  • Immunity. 2018;48(4):773-786.e5.

    Li J, et al. Co-inhibitory molecule b7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor cd8+ t cells.

Custom services

Bio X Cell offers custom antibody engineering and recombinant production services designed to support both in vivo and in vitro research applications. Their expertise includes species and isotype switching, Fc engineering, and sequence-defined recombinant expression in mammalian systems such as CHO and HEK293 cells. Antibodies are produced with high batch-to-batch consistency, purified using Protein A/G chromatography, and subjected to stringent quality control testing, including low endotoxin levels appropriate for in vivo studies.

In addition to recombinant engineering, Bio X Cell provides antibody production services from existing hybridoma or stable cell lines. Manufacturing processes are optimized for scalability, enabling production from milligram to gram quantities. After purification, antibodies are formulated in preservative-free buffer systems suitable for preclinical research applications.

Through Bio-Connect, customers can access Bio X Cell’s custom engineering and production services with local scientific support. Our team helps translate research objectives into clear technical specifications, coordinates communication throughout the project, and ensures efficient delivery of high-quality antibodies tailored to specific in vivo and in vitro research needs.

More about Bio X Cell

Sign up for our research newsletter

We gladly support you by keeping you updated on our latest products and developments


Need help? Contact our technical support
Contact